CN114989138B - 沃诺拉赞盐及其晶型、制备方法和用途 - Google Patents
沃诺拉赞盐及其晶型、制备方法和用途 Download PDFInfo
- Publication number
- CN114989138B CN114989138B CN202210201812.7A CN202210201812A CN114989138B CN 114989138 B CN114989138 B CN 114989138B CN 202210201812 A CN202210201812 A CN 202210201812A CN 114989138 B CN114989138 B CN 114989138B
- Authority
- CN
- China
- Prior art keywords
- salt
- flurbiprofen
- vonoprazan
- voronoi
- vorexant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- BFDBKMOZYNOTPK-UHFFFAOYSA-N vonoprazan Chemical group C=1C=CN=CC=1S(=O)(=O)N1C=C(CNC)C=C1C1=CC=CC=C1F BFDBKMOZYNOTPK-UHFFFAOYSA-N 0.000 title claims abstract description 41
- 239000013078 crystal Chemical group 0.000 title abstract description 13
- 238000002360 preparation method Methods 0.000 title abstract description 11
- 229950003825 vonoprazan Drugs 0.000 claims abstract description 77
- 150000003839 salts Chemical class 0.000 claims abstract description 49
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 claims abstract description 46
- 229960002390 flurbiprofen Drugs 0.000 claims abstract description 31
- 239000003814 drug Substances 0.000 claims abstract description 18
- 201000010099 disease Diseases 0.000 claims abstract description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 14
- 210000004211 gastric acid Anatomy 0.000 claims abstract description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 24
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 23
- 239000007787 solid Substances 0.000 claims description 17
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 10
- 239000003960 organic solvent Substances 0.000 claims description 6
- 238000004090 dissolution Methods 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- SYTBZMRGLBWNTM-JTQLQIEISA-N (S)-flurbiprofen Chemical compound FC1=CC([C@@H](C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-JTQLQIEISA-N 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims description 2
- 238000001816 cooling Methods 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 claims description 2
- 229940011051 isopropyl acetate Drugs 0.000 claims description 2
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000001376 precipitating effect Effects 0.000 claims 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 abstract description 22
- 229960001259 diclofenac Drugs 0.000 abstract description 22
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 abstract description 11
- 230000000202 analgesic effect Effects 0.000 abstract description 11
- 238000010253 intravenous injection Methods 0.000 abstract description 10
- 229940079593 drug Drugs 0.000 abstract description 9
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 abstract description 8
- 239000001530 fumaric acid Substances 0.000 abstract description 3
- -1 isopropyl ester Chemical class 0.000 description 27
- ROGSHYHKHPCCJW-WLHGVMLRSA-N (e)-but-2-enedioic acid;1-[5-(2-fluorophenyl)-1-pyridin-3-ylsulfonylpyrrol-3-yl]-n-methylmethanamine Chemical compound OC(=O)\C=C\C(O)=O.C=1C=CN=CC=1S(=O)(=O)N1C=C(CNC)C=C1C1=CC=CC=C1F ROGSHYHKHPCCJW-WLHGVMLRSA-N 0.000 description 17
- 239000012065 filter cake Substances 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 12
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 10
- 241000700159 Rattus Species 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 208000007107 Stomach Ulcer Diseases 0.000 description 8
- 208000025865 Ulcer Diseases 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 201000005917 gastric ulcer Diseases 0.000 description 8
- 231100000397 ulcer Toxicity 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 6
- 230000002496 gastric effect Effects 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 238000005286 illumination Methods 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 229940126409 proton pump inhibitor Drugs 0.000 description 5
- 239000000612 proton pump inhibitor Substances 0.000 description 5
- 208000000718 duodenal ulcer Diseases 0.000 description 4
- 230000027119 gastric acid secretion Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 229920001304 Solutol HS 15 Polymers 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 206010020601 Hyperchlorhydria Diseases 0.000 description 2
- 102100021904 Potassium-transporting ATPase alpha chain 1 Human genes 0.000 description 2
- 108010083204 Proton Pumps Proteins 0.000 description 2
- 206010042220 Stress ulcer Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 2
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- IVWNRMYVRYIRNC-UHFFFAOYSA-N CNCC(C=C1C(C=CC=C2)=C2F)=CN1S(C1=CNC=C1)(=O)=O Chemical compound CNCC(C=C1C(C=CC=C2)=C2F)=CN1S(C1=CNC=C1)(=O)=O IVWNRMYVRYIRNC-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010063655 Erosive oesophagitis Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- VKEQBMCRQDSRET-UHFFFAOYSA-N Methylone Chemical compound CNC(C)C(=O)C1=CC=C2OCOC2=C1 VKEQBMCRQDSRET-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000005496 eutectics Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 229960003174 lansoprazole Drugs 0.000 description 1
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 229960005010 orotic acid Drugs 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229940126535 potassium competitive acid blocker Drugs 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
- C07C227/18—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions involving amino or carboxyl groups, e.g. hydrolysis of esters or amides, by formation of halides, salts or esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/42—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/41—Preparation of salts of carboxylic acids
- C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
- C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明提供了沃诺拉赞盐及其晶型、制备方法和用途,所述盐选自沃诺拉赞与氟比洛芬所成盐、或沃诺拉赞与双氯酚酸所成盐。本发明通过沃诺拉赞和双氯酚酸或者氟比洛芬成盐,以期望开发成静脉给药的注射剂,且解决对口服沃诺拉赞富马酸片不适用病人用药的问题。此外,沃诺拉赞和双氯酚酸或者氟比洛芬成盐,能充分发挥药物的配伍作用,可用于临床上预防和/或治疗胃酸类疾病,并同时对病人起到一定的镇痛作用,以及具有较好药用安全性,有望开发出一种更好的预防和/或治疗胃酸类疾病同时具有镇痛效果的药物。
Description
本申请要求于2021年3月2日提交中国专利局、申请号为202110230710.3发明名称为“沃诺拉赞盐、及其晶型与制备方法和用途”的中国专利申请的优先权,其全部内容通过引用结合在本申请中。
技术领域
本发明涉及化学药物领域,具体涉及一种沃诺拉赞盐及其晶型、制备方法和用途。
背景技术
胃酸相关性疾病是一类由于胃酸分泌过多或对胃酸特别敏感而引起的疾病,如消化性溃疡、胃食管返流及非甾体类抗炎药物引起的消化系统病等。目前治疗胃酸分泌过多的最强药物是质子泵抑制剂(PPI),例如奥美拉唑、兰索拉唑等。但该类药物存在着严重缺陷:夜间会发生酸反跳现象,影响治疗效果。钾离子竞争性酸阻滞剂(P-CAB)类药物(如沃诺拉赞)的出现很好的解决了这一类问题,通过竞争性抑制质子泵(H+,K+-ATPase)中K+而起作用,临床上可明显减少夜间酸反跳现象的发生。
沃诺拉赞(Vonoprazan),又称伏诺拉生,其化学名为1-[5-(2-氟苯基)-1-(吡咯-3-基磺酰基)-1H-吡咯-3-基]-N-甲基甲胺,结构式如式(Ⅳ)所示。沃诺拉赞由武田制药公司研制,是全球第一个可逆的钾离子竞争性酸阻滞剂(P-CAB)。2015年2月,沃诺拉赞在日本批准上市,上市盐型为富马酸盐,上市剂型为片剂。
体外实验研究表明沃诺拉赞抑制质子泵的能力是常规质子泵抑制剂兰索拉唑的400倍,其相对于Na+、K+-ATPase的抑制选择性在1000倍以上,可有效地抑制胃酸分泌。沃诺拉赞具有抑制胃酸分泌强劲、持久、起效快等特点,是新一代的抗胃酸分泌药物。
质子泵抑制剂在临床中有胃肠道给药途径及静脉给药途径两种形式,胃肠道给药的质子泵抑制剂主要应用于“胃溃疡、十二指肠溃疡”等适应症,而静脉给药途径的质子泵抑制剂则应用于“预防应激性溃疡”,临床中主要应用于预防应激状态时并发的急性胃粘膜损伤。应激性溃疡是由于严重创伤、烧伤、重型颅脑损伤、手术及其他重大疾病引起的急性胃粘膜糜烂、溃疡,常并发上消化道出血而威胁生命。目前,沃诺拉赞暂未开发静脉给药产品,中国专利CN105693693A,公开了沃诺拉赞的各种有机酸或无机酸的盐,如富马酸盐、醋酸盐、甲磺酸盐、硫酸盐、磷酸盐、L-苹果酸盐、枸橼酸盐。中国专利CN107759568A,公开了沃诺拉赞双盐酸盐、双磷酸盐、苯磺酸盐、1,4-丁二酸磺酸半盐、2-羟基乙磺酸盐和L-酒石酸盐等。韩国专利KR1020200120177A,公开了沃诺拉赞与乳清酸的盐,但这些都是纯粹的改变盐型,并对各盐的溶解度和稳定性等理化性质进行了考察,未见对各盐药理性质进行研究,而化合物的药理性质将直接影响到药物剂型的开发和临床应用。
发明内容
为解决上述技术问题,本发明进一步对沃诺拉赞成盐进行了研究,提供了沃诺拉赞的新型盐及其晶型,其与现有的沃诺拉赞盐相比,具有更好的稳定性,特别是光照稳定性,以期望开发成静脉给药的注射剂,解决对口服沃诺拉赞富马酸片不适用病人用药的问题,提高临床用药顺应性,可用于临床上预防应激状态时并发的急性胃粘膜损伤。此外,沃诺拉赞和双氯酚酸或者氟比洛芬成盐,能充分发挥药物的配伍作用,并可在预防和/或治疗胃酸类疾病的同时起到镇痛的效果,以及具有较好药用安全性。
本发明提供的沃诺拉赞盐,选自沃诺拉赞与氟比洛芬所成盐、或沃诺拉赞与双氯酚酸所成盐。
进一步的,沃诺拉赞与氟比洛芬所成盐具有式(Ⅰ)所示结构;
优选的,氟比洛芬可选自(S)-氟比洛芬,具有如下式(Ⅱ)所示结构;
沃诺拉赞与双氯酚酸所成盐具有式(Ⅲ)所示结构;
本发明进一步提供了沃诺拉赞与氟比洛芬所成盐的晶型,其为式(Ⅰ)所示的沃诺拉赞与氟比洛芬所成盐的X射线粉末衍射图在2theta值为5.02、6.699、9.598、13.761、14.241、15.019、15.563、16.96、17.799、18.38、19.28、20.061、20.72、21.38、22.22、23.259、24.74、26.081、27.401、30.32处具有特征峰。
进一步的,所述沃诺拉赞与氟比洛芬所成盐的晶型的X射线粉末衍射图还在2theta值为9.981、12.6、16.461、24.22、25.721、28.92、31.76、34.121中的一处或多处具有特征峰。
更进一步的,本发明提供的沃诺拉赞与氟比洛芬所成盐的晶型具有如图1所示的X射线粉末衍射图谱所代表的特征。
本发明进一步提供了沃诺拉赞与双氯酚酸所成盐的晶型,其为式(Ⅲ)所示的沃诺拉赞与双氯酚酸所成盐的X射线粉末衍射图在2theta值为7.698、12.02、12.939、13.157、13.96、14.119、14.498、16.095、17.804、18.06、19.419、20.239、20.642、21.82、22.24、22.961、23.236、23.88、24.299、25.419、27.62、28、30.502处具有特征峰。
进一步的,所述沃诺拉赞与双氯酚酸所成盐的晶型的X射线粉末衍射图还在2theta值为9.28、11.4、15.379、17.297、18.579、25.004、25.8、26.04、28.58、29.06、29.583、30.919、34.14、34.561中的一处或多处具有特征峰。
更进一步的,本发明提供的沃诺拉赞与双氯酚酸所成盐的晶型具有如图2所示的X射线粉末衍射图谱所代表的特征。
本发明的另一方面提供了沃诺拉赞与氟比洛芬所成盐的晶型的制备方法,所述制备方法为将氟比洛芬和沃诺拉赞加入有机溶剂中,加热温度至40℃至60℃搅拌溶解,溶解后慢慢析出固体,再降温至-10℃至20℃;所述有机溶剂为甲基叔丁基醚、乙酸乙酯、乙酸异丙酯中的一种或多种。
本发明的再一方面提供了沃诺拉赞与双氯酚酸所成盐的晶型的制备方法,所述制备方法为将双氯酚酸和沃诺拉赞加入有机溶剂中,搅拌溶解,溶解后慢慢析出固体;所述有机溶剂为乙酸乙酯、异丙酯中的一种,或乙酸乙酯、异丙醇中的一种和甲基叔丁基醚的混合体系。
本发明的再一方面提供了一种包含有效量的本发明所述的沃诺拉赞盐和至少一种药学上可接受的添加剂的药物组合物。所述药物组合物的剂型优先选自注射剂,具体包括注射液、冻干粉针、输液剂等。
根据本发明的目的,本发明的再一方面提供了所述沃诺拉赞盐及其药物组合物在制备用于预防和/或治疗胃酸类疾病药物方面的用途。如胃酸过多而引起的相关疾病,包括糜烂性食管炎、胃溃疡、十二指肠溃疡、幽门螺杆菌病等。
本发明所述的“盐”不仅包括沃诺拉赞与相应的酸通过离子键作用结合的经典意义上的盐,而且还包括沃诺拉赞与相应的酸通过氢键等共价键的作用结合而共存的化合物,即本发明所述的“盐”包括本技术领域熟知的经典意义上的盐、共晶或它们的混合形式等。本发明所述的“盐”还进一步包括它的多晶、溶剂合物、溶剂合物多晶、水合物、水合物多晶等形式。
本发明通过沃诺拉赞和双氯酚酸或者氟比洛芬成盐,具有较好的稳定性,特别是光照稳定性,以期望开发成静脉给药的注射剂,解决对口服沃诺拉赞富马酸片不适用病人用药的问题,提高临床用药顺应性,可用于临床上预防应激状态时并发的急性胃粘膜损伤。此外,沃诺拉赞和双氯酚酸或者氟比洛芬成盐,能充分发挥药物的配伍作用,可用于临床上预防和/或治疗胃酸类疾病,并同时对病人起到一定的镇痛作用,以及具有较好药用安全性,有望开发出一种更好的预防和/或治疗胃酸类疾病同时具有镇痛效果的药物。
当然,实施本发明的任一实施方案并不一定需要同时达到以上所述的所有优点。
附图说明
为了更清楚地说明本发明实施例的技术方案,下面将对实施例描述中所需要使用的附图作简单地介绍,显而易见地,下面描述中的附图仅仅是本发明的一些实施例,对于本领域普通技术人员来讲,还可以根据这些附图获得其它的实施例。
图1为沃诺拉赞与氟比洛芬所成盐的晶型的X射线粉末衍射图谱;
图2为沃诺拉赞与双氯酚酸所成盐的晶型的X射线粉末衍射图谱。
具体实施方式
下面将结合本发明实施方案中的附图,对本发明实施方案中的技术方案进行清楚、完整地描述,显然,所描述的实施方案仅仅是本发明一部分实施方案,而不是全部的实施方案。基于本发明中的实施方案,本领域普通技术人员基于本发明所获得的所有其它实施方案,都属于本发明保护的范围。
实施例1
沃诺拉赞与氟比洛芬所成盐及其晶型的制备
试验1
将氟比洛芬(1.00g,4.1mmol,1.0eq)和沃诺拉赞(1.49g,4.3mmol,1.05eq)加入到20mL甲基叔丁基醚中,45℃搅拌溶解,溶解后慢慢析出白色固体,再降温至15℃,搅拌5h,抽滤,滤饼用5mL甲基叔丁基醚淋洗,滤饼45℃真空干燥,得白色固体2.10g,收率86.8%。
核磁共振光谱数据:1H NMR(400MHz,MeOD)δ8.79(dd,J=4.9,1.4Hz,1H),8.53(d,J=2.2Hz,1H),7.90–7.81(m,1H),7.76(d,J=1.7Hz,1H),7.60–7.26(m,8H),7.26–7.14(m,3H),7.15–7.02(m,2H),6.41(d,J=1.8Hz,1H),4.01(s,2H),3.63(q,J=7.1Hz,1H),2.64(s,3H),1.44(d,J=7.1Hz,3H).
所测得的沃诺拉赞与氟比洛芬所成盐的粉末X射线衍射图谱见图1,其晶型数据见如下表1,其中相对强度是指以15号峰的强度为基准计算得到;
表1
试验2
将氟比洛芬(1.00g,4.1mmol,1.0eq)和沃诺拉赞(1.49g,4.3mmol,1.05eq)加入到20mL甲基叔丁基醚和2mL乙酸乙酯中,45℃搅拌溶解,溶解后慢慢析出白色固体,再降温至15℃,搅拌8h,抽滤,滤饼用5mL甲基叔丁基醚淋洗,滤饼45℃真空干燥,得白色固体1.95g,收率80.9%。定性显示得到的产物与试验1相同。
实施例2
将(S)-氟比洛芬(1.00g,4.1mmol,1.0eq)和沃诺拉赞(1.49g,4.3mmol,1.05eq)加入到30mL甲基叔丁基醚,45℃搅拌溶解,溶解后慢慢析出白色固体,再降温至15℃,搅拌过夜,抽滤,滤饼用5mL甲基叔丁基醚淋洗,滤饼45℃真空干燥,得白色固体1.75g,收率72.6%。
核磁共振光谱数据:1H NMR(400MHz,CDCl3)δ8.73(dd,J=4.8,1.4Hz,1H),8.56(d,J=2.1Hz,1H),7.70–7.65(m,1H),7.53–7.31(m,7H),7.29(dd,J=6.4,3.6Hz,2H),7.18–7.05(m,4H),6.99(t,J=8.9Hz,1H),6.30(d,J=1.7Hz,1H),3.68(s,2H),3.63(dd,J=14.3,7.2Hz,1H),2.35(s,3H),1.46(d,J=7.2Hz,3H).
实施例3
沃诺拉赞与双氯酚酸所成盐及其晶型的制备
试验1
将双氯酚酸(1.00g,3.4mmol,1.0eq)和沃诺拉赞(1.22g,3.5mmol,1.05eq)加入到10mL乙酸乙酯中,室温搅拌溶解,溶解后慢慢析出白色固体,搅拌5h,抽滤,滤饼用2mL乙酸乙酯淋洗,滤饼45℃真空干燥,得白色固体1.90g,收率87.6%。
核磁共振光谱数据:1H NMR(400MHz,MeOD)δ8.77(dd,J=4.9,1.5Hz,1H),8.51(d,J=2.1Hz,1H),7.84(ddd,J=8.2,2.2,1.6Hz,1H),7.76(d,J=1.7Hz,1H),7.53–7.44(m,2H),7.36(d,J=8.1Hz,2H),7.20–7.12(m,2H),7.11–6.98(m,3H),6.95(td,J=7.9,1.5Hz,1H),6.80(td,J=7.4,1.0Hz,1H),6.38(d,J=1.8Hz,1H),6.33(d,J=7.9Hz,1H),4.01(s,2H),3.62(s,2H),2.62(s,3H).
所测得的沃诺拉赞与双氯酚酸所成盐的粉末X射线衍射图谱见图2,其晶型数据见如下表2,其中相对强度是指以6号峰的强度为基准计算得到;
表2
试验2
将双氯酚酸(1.00g,3.4mmol,1.0eq)和沃诺拉赞(1.22g,3.5mmol,1.05eq)加入到10mL异丙醇中,室温搅拌溶解,溶解后慢慢析出白色固体,搅拌5h,抽滤,滤饼用2mL异丙醇淋洗,滤饼45℃真空干燥,得白色固体1.98g,收率91.2%。定性显示得到的产物与试验1相同。
试验3
将双氯酚酸(500mg,1.7mmol,1.0eq)和沃诺拉赞(610g,1.75mmol,1.05eq)加入到1mL乙酸乙酯和5mL甲基叔丁基醚中,室温搅拌溶解,溶解后慢慢析出白色固体,搅拌5h,抽滤,滤饼用2mL甲基叔丁基醚淋洗,滤饼45℃真空干燥,得白色固体1.0g,收率92.6%。定性显示得到的产物与试验1相同。
试验4
将双氯酚酸(500mg,1.7mmol,1.0eq)和沃诺拉赞(610g,1.75mmol,1.05eq)加入到1mL异丙醇和5mL甲基叔丁基醚中,室温搅拌溶解,溶解后慢慢析出白色固体,搅拌5h,抽滤,滤饼用2mL甲基叔丁基醚淋洗,滤饼45℃真空干燥,得白色固体0.96g,收率88.9%。定性显示得到的产物与试验1相同。
实施例4
本发明沃诺拉赞盐的药代动力学研究
大鼠药代动力学研究
实验方法:雄性SD大鼠(200-300g)20只,随机分成2组(n=10):沃诺拉赞富马酸盐、沃诺拉赞氟比洛芬盐。分别静脉注射沃诺拉赞富马酸盐(8.4mg/kg),沃诺拉赞氟比洛芬盐(10.7mg/kg),其中以上各组为等摩尔沃诺拉赞给药,各组给药体积为5ml·kg-1。分别于给药前和给药后5min,15min,30min,45min,1h,1.5h,2h,4h,8h取血,离心取血浆,检测血浆中沃诺拉赞浓度和氟比洛芬浓度。实验结果见表3、表4;
表3大鼠静脉给药后血浆中沃诺拉赞药代动力学参数(Mean±SD)
实验结论:沃诺拉赞富马酸盐、沃诺拉赞氟比洛芬盐血浆中沃诺拉赞的AUC0-t(h*ng/mL)分别为1342.0和1418.6,两者相比,沃诺拉赞氟比洛芬盐的AUC0-t有所提高。此外,沃诺拉赞富马酸盐、沃诺拉赞氟比洛芬盐血浆中沃诺拉赞的半衰期、药峰浓度、清除率均无显著差异,药时曲线走势一致,说明两者给药后血浆中沃诺拉赞在体内吸收代谢较一致,沃诺拉赞氟比洛芬盐能发挥较好的预防和/或治疗胃酸类疾病的药效。
表4大鼠静脉给药后血浆中氟比洛芬药代动力学参数(Mean±SD)
沃诺拉赞氟比洛芬盐 | |
半衰期HL_Lambda_z(T1/2,h) | 3.41±0.4 |
药峰浓度Cmax(ng/mL) | 38525.3±262.3 |
药时曲线下面积AUC0-t(h*ng/mL) | 162599.3±7881.4 |
清除率Cl_pred(L/h/kg) | 0.022±0.0021 |
实验结论:实验结果表明沃诺拉赞氟比洛芬盐血浆中氟比洛芬的AUC0-t(h*ng/mL)为162599.3,具有较高的暴露量,说明沃诺拉赞氟比洛芬盐能发挥较好的镇痛药效。
比格犬药代动力学研究
实验方法:雄性比格犬(8-10kg)6只,随机分成2组(n=3):沃诺拉赞富马酸盐、沃诺拉赞氟比洛芬盐。分别静脉注射沃诺拉赞富马酸盐(2.5mg/kg),沃诺拉赞氟比洛芬盐(3.2mg/kg),其中以上各组为等摩尔沃诺拉赞给药,各组给药体积为1ml·kg-1。分别于给药前和给药后5min,15min,30min,1h,2h,4h,6h,8h,12h,24h取血,离心取血浆,检测血浆中沃诺拉赞浓度。实验结果见表5:
表5比格犬静脉给药后血浆中沃诺拉赞药代动力学参数(Mean±SD)
沃诺拉赞富马酸盐 | 沃诺拉赞氟比洛芬盐 | |
半衰期HL_Lambda_z(T1/2,h) | 1.35 | 1.73 |
药峰浓度Cmax(ng/mL) | 1056.4±127.3 | 1088.9±189.2 |
药时曲线下面积AUC0-t(h*ng/mL) | 2875.2±198.6 | 4789.5±254.3 |
清除率Cl_pred(L/h/kg) | 0.73±0.24 | 0.41±0.12 |
实验结论:沃诺拉赞富马酸盐、沃诺拉赞氟比洛芬盐血浆中沃诺拉赞的AUC0-t(h*ng/mL)分别为2875.2和4789.5,两者相比,沃诺拉赞氟比洛芬盐的AUC0-t有较大的提高,说明沃诺拉赞氟比洛芬盐改善了药代动力学性质,提高了沃诺拉赞在体内的暴露量,表现在临床上有潜力降低给药剂量。
实施例5本发明沃诺拉赞盐的药效研究
抗胃溃疡药效研究
实验方法:雄性SD大鼠,根据体重随机分组,每组8只,分为6组(Sham组(假手术组)、Vehicle组(模型组)、沃诺拉赞富马酸盐2.67mg/kg组、沃诺拉赞氟比洛芬盐0.34mg/kg组、沃诺拉赞氟比洛芬盐1.02mg/kg组、沃诺拉赞氟比洛芬盐3.41mg/kg组),其中沃诺拉赞富马酸盐2.67mg/kg组与沃诺拉赞氟比洛芬盐3.41mg/kg组为等摩尔剂量给药(以沃诺拉赞计,相当于推荐的人临床给药剂量20mg),溶媒为5%二甲基亚砜(DMSO)+10%Solutol(HS-15)+85%生理盐水(saline),其中沃诺拉赞富马酸盐2.67mg/kg组为口服给药,其他组均为静脉注射给药。动物禁食24小时后,给溶媒或化合物,给药后1小时,动物进行胃幽门结扎手术,结扎后,禁食禁水9小时。在禁食禁水9小时后,动物安乐死,取胃部铺平,测量胃溃疡长和宽,计算溃疡面积,评价溃疡指数。溃疡评分标准和实验结果见表6、表7:
表6Okabe法溃疡评分标准
表7大鼠Okabe法溃疡评分结果
组别 | 溃疡评分(Okabe法) |
Sham | 0.00±0.000*** |
Vehicle | 2.69±0.619 |
沃诺拉赞富马酸盐2.67mg/kg | 1.00±0.500** |
沃诺拉赞氟比洛芬盐0.34mg/kg | 0.75±0.231** |
沃诺拉赞氟比洛芬盐1.02mg/kg | 0.19±0.091*** |
沃诺拉赞氟比洛芬盐3.41mg/kg | 0.06±0.063*** |
数据标*表示与vehicle相比有显著差异,**P<0.01,***P<0.001。
实验结论:各组与Vehicle组相比溃疡指数均显著降低,其中口服给药沃诺拉赞富马酸盐2.67mg/kg组和低剂量静脉注射给药沃诺拉赞氟比洛芬盐0.34mg/kg组抗胃溃疡作用效果一致,都有显著的抗胃溃疡作用。且沃诺拉赞氟比洛芬盐随着剂量增加,抗胃溃疡作用效果增强,呈剂量依赖性。说明静脉注射给药沃诺拉赞氟比洛芬盐有抗胃溃疡作用效果,随着剂量增加,抗胃溃疡作用效果增强,且静脉注射给药沃诺拉赞氟比洛芬盐的同等效应剂量是口服给药沃诺拉赞富马酸盐的十分之一左右(以沃诺拉赞摩尔剂量比),有望将本发明提供的新型沃诺拉赞盐开发成静脉给药的注射剂。
镇痛药效研究
实验方法:雄性SD大鼠,根据体重随机分组,每组10只,分为3组(Vehicle组、沃诺拉赞氟比洛芬盐1.02mg/kg组、沃诺拉赞氟比洛芬盐3.41mg/kg组),溶媒为5%DMSO+10%Solutol(HS-15)+85%saline,静脉注射给药20min后分别腹腔注射0.7%的醋酸溶液(10ml/kg),并于5min后开始记录随后15min内(即6-20min)扭体反应次数,计算抑制率。结果见表8:
表8大鼠醋酸扭体数据表
数据标*表示与vehicle相比有显著差异,*P<0.05,**P<0.01。
实验结论:沃诺拉赞氟比洛芬盐具有镇痛作用效果,并且随着剂量增加,镇痛作用效果增强,呈剂量依赖性。
综上所述,沃诺拉赞氟比洛芬盐可在预防和/或治疗胃酸类疾病的同时起到镇痛的效果,有望开发成一种具有更好的预防和/或治疗胃酸类疾病的同时具有镇痛效果的药物。
实施例6本发明沃诺拉赞盐的安全性研究
14天重复给药毒性研究
实验方法:SD大鼠,每组10只,雌雄各半,溶媒5%DMSO+10%Solutol(HS-15)+85%saline,分为4组(Vehicle组、沃诺拉赞氟比洛芬盐0.5mg/kg组、沃诺拉赞氟比洛芬盐1.5mg/kg组、沃诺拉赞氟比洛芬盐5mg/kg组),按设计剂量动物连续静脉注射给药14天(每天一次),给药结束后恢复14天。动物数为40只,实验过程中分别进行体重、摄食量、临床观察与检查;给药末期和恢复期末处理,分别进行大体解剖、脏器称重、血液学指标、凝血指标、血生化指标检测。
实验结论:沃诺拉赞氟比洛芬盐各剂量组静脉注射给药14天与同期Vehicle组比较,各指标无明显差异或差异无毒理学意义,说明沃诺拉赞氟比洛芬盐在剂量5mg/kg大鼠静脉注射14天无显著毒性现象,体现出良好的安全性。
实施例7沃诺拉赞盐的稳定性试验考察
高温稳定性考察步骤:将沃诺拉赞富马酸盐、沃诺拉赞氟比洛芬盐分别置于高温60℃下,再分别检测其在高温60℃下不同时间段的峰面积和活性成分含量,实验结果见表9;
光照稳定性考察步骤:将沃诺拉赞富马酸盐、沃诺拉赞氟比洛芬盐分别置于光照(4500Lux)下,在分别检测其在光照(4500Lux)下不同时间段的峰面积和活性成分含量,实验结果见表9;
表9稳定性测试结果
注:表9中的“/”表示未测试对应的数据。
实验结论:高温60℃下沃诺拉赞富马酸盐、沃诺拉赞氟比洛芬盐两者都稳定,光照下,沃诺拉赞氟比洛芬盐比沃诺拉赞富马酸盐具有更好的稳定性。
需要说明的是,在本文中,诸如第一和第二等之类的关系术语仅仅用来将一个实体或操作与另一个实体或操作区分开来,而不一定要求或者暗示这些实体之间存在任何这种实际的关系或者顺序。而且,术语“包括”、“包含”或者其任何其它变体意在涵盖非排他性的包含,从而使得包括一系列要素的过程、方法、物品或者设备不仅包括那些要素,而且还包括没有明确列出的其它要素,或者是还包括为这种过程、方法、物品或者设备所固有的要素。
本说明书中的各个实施方案均采用相关的方式描述,各个实施方案之间相同相似的部分互相参见即可,每个实施方案重点说明的都是与其它实施例的不同之处。
以上所述仅为本发明的较佳实施例,并不用以限制本发明,凡在本发明的精神和原则之内,所做的任何修改、等同替换、改进等,均应包含在本发明保护的范围之内。
Claims (8)
1.一种沃诺拉赞盐,其特征在于选自:沃诺拉赞与氟比洛芬所成盐。
4.一种根据权利要求2所述的沃诺拉赞盐的晶型,其特征在于,所述晶型为式(Ⅰ)所示的沃诺拉赞与氟比洛芬所成盐的晶型,所述晶型为式(Ⅰ)所示的沃诺拉赞与氟比洛芬所成盐的X射线粉末衍射图在2theta值为5.02、6.699、9.598、13.761、14.241、15.019、15.563、16.96、17.799、18.38、19.28、20.061、20.72、21.38、22.22、23.259、24.74、26.081、27.401、30.32处具有特征峰。
5.根据权利要求4所述的晶型,其特征在于,所述沃诺拉赞与氟比洛芬所成盐的X射线粉末衍射图还在2theta值为9.981、12.6、16.461、24.22、25.721、28.92、31.76、34.121中的一处或多处具有特征峰。
6.一种根据权利要求4或5所述的沃诺拉赞与氟比洛芬所成盐的晶型的制备方法,其特征在于,所述制备方法为将氟比洛芬和沃诺拉赞加入有机溶剂中,加热温度至40℃至60℃搅拌溶解,溶解后慢慢析出固体,再降温至-10℃至20℃;所述有机溶剂为甲基叔丁基醚、乙酸乙酯、乙酸异丙酯中的一种或多种。
7.一种包含有效量的如权利要求1至3中任一项所述的沃诺拉赞盐和至少一种药学上可接受的添加剂的药物组合物。
8.根据权利要求1至3中任一项所述的沃诺拉赞盐或权利要求7所述的药物组合物在制备用于预防和/或治疗胃酸类疾病药物中的用途。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2021102307103 | 2021-03-02 | ||
CN202110230710 | 2021-03-02 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114989138A CN114989138A (zh) | 2022-09-02 |
CN114989138B true CN114989138B (zh) | 2023-06-13 |
Family
ID=83023739
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210201812.7A Active CN114989138B (zh) | 2021-03-02 | 2022-03-02 | 沃诺拉赞盐及其晶型、制备方法和用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114989138B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116966180B (zh) * | 2022-11-10 | 2024-05-14 | 山东道合药业有限公司 | 沃诺拉赞焦谷氨酸盐的片剂、注射剂、复方制剂 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS52473B9 (sr) * | 2005-08-30 | 2019-07-31 | Takeda Pharmaceuticals Co | 1-heterociklilsulfonil, 2-aminometil, 5-(hetero-)aril supstituisani derivati 1-h-pirola kao inhibitori sekrecije kiseline |
CN107759568A (zh) * | 2016-08-22 | 2018-03-06 | 四川海思科制药有限公司 | 沃诺拉赞盐、晶型及其制备方法和用途 |
CN106892900A (zh) * | 2017-04-10 | 2017-06-27 | 山东裕欣药业有限公司 | 一种富马酸沃诺拉赞及其制备方法 |
CN108689991B (zh) * | 2018-06-11 | 2019-12-20 | 杭州中美华东制药有限公司 | 沃诺拉赞新晶型盐及其制备方法 |
-
2022
- 2022-03-02 CN CN202210201812.7A patent/CN114989138B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN114989138A (zh) | 2022-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI657826B (zh) | Complex of angiotensin II receptor antagonist metabolite and NEP inhibitor and preparation method thereof | |
US8748482B2 (en) | Lubiprostone crystal, the use and the method for the preparation thereof | |
JP7264999B2 (ja) | 2-(1-アシルオキシ-n-ペンチル)安息香酸と塩基性アミノ酸またはアミノグアニジンによって形成される塩と、その製造方法及び用途 | |
RU2600986C2 (ru) | Органические аминные соли азилсартана, способ их получения и применение | |
JP2009514856A (ja) | 医薬品ガリウム組成物及び方法 | |
CN114989138B (zh) | 沃诺拉赞盐及其晶型、制备方法和用途 | |
US20070060544A1 (en) | 4-Nitro-2-[(4'-methoxy)-phenoxy]-methanesulfonanilide derivatives and their pharmaceutical use | |
CN115304593A (zh) | 苯并异噻唑化合物及其药物组合物和应用 | |
WO2011160597A1 (zh) | 一种具有降高血压活性的呋喃香豆素类化合物及其制备方法 | |
US20210087144A1 (en) | Insoluble complex or solvate thereof, pharmaceutical compostion and use thereof | |
WO2015042495A2 (en) | Metformin salts to treat type2 diabetes | |
CN112839934B (zh) | 一种沃诺拉赞盐及其制备方法与用途 | |
KR20190090729A (ko) | 토파시티닙의 신규 염, 이의 제조방법 및 이를 포함하는 약학 조성물 | |
CN111635430A (zh) | 一种非甾体化合物、其制备方法和用途 | |
WO2018068696A1 (zh) | 一种青藤碱及其衍生物的peg修饰物、其制备方法和用途 | |
CN113402390B (zh) | 一种阿司匹林药物共晶体及其制备方法和应用 | |
JPS6052747B2 (ja) | 2−置換フエニル−5−アルキルチアゾリジン−4−オン、及び該化合物有効成分とする抗消化性潰瘍剤 | |
US11382867B2 (en) | Apomorphine-palmitic acid cocrystal solid particle crystalline form | |
WO2022011752A1 (zh) | 一种沃诺拉赞盐及其制备方法与用途 | |
US8846766B2 (en) | Abuse-deterrent methadone for the safe treatment of drug abuse and pain relief | |
WO2023245470A1 (zh) | Mdp类似物在制备用于治疗炎症性肠病的药物中的用途 | |
CN116462659A (zh) | 一种伏诺拉生盐、其晶型及其制备方法与应用 | |
CN109879839B (zh) | 6-哌嗪甲基-7-羟基苯并呋喃类化合物及其医药用途 | |
JPH035425A (ja) | 抗潰瘍剤 | |
CN115246863A (zh) | 一种川芎嗪四价铂类化合物、其制备方法及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Vonolazan salt and its crystal form, preparation method, and application Granted publication date: 20230613 Pledgee: China Co truction Bank Corp Changsha branch Pledgor: TIANDI HENGYI PHARMACEUTICAL Co.,Ltd. Registration number: Y2024980013202 |